Publications
- New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates--Nrf2 activators and GSK-3 inhibitors2012 | First Faculty of Medicine
- Biological hypotheses, risk factors, and biomarkers of schizophrenia2023 | First Faculty of Medicine
- Different Effects of SSRIs, Bupropion, and Trazodone on Mitochondrial Functions and Monoamine Oxidase Isoform Activity2023 | First Faculty of Medicine
- Age-Dependent Alterations in Platelet Mitochondrial Respiration2023 | First Faculty of Medicine
- Development of submicromolar 17 beta-HSD10 inhibitors and their in vitro and in vivo evaluation2023 | First Faculty of Medicine
- Agomelatine, Ketamine and Vortioxetine Attenuate Energy Cell Metabolism-In Vitro Study2022 | First Faculty of Medicine
- Linking the Amyloid, Tau, and Mitochondrial Hypotheses of Alzheimer's Disease and Identifying Promising Drug Targets2022 | First Faculty of Medicine
- Effects of novel 17 beta-hydroxysteroid dehydrogenase type 10 inhibitors on mitochondrial respiration2021 | First Faculty of Medicine
- Effects of Novel Tacrine Derivatives on Mitochondrial Energy Metabolism and Monoamine Oxidase Activity-In Vitro Study2021 | First Faculty of Medicine
- Novel approaches in schizophrenia-from risk factors and hypotheses to novel drug targets2021 | First Faculty of Medicine
Loading network view...